Navigation Links
PTC Therapeutics Awarded $1.6 Million FDA Orphan Drug Grant to Support an Ongoing Phase 3 Study in Cystic Fibrosis
Date:9/21/2010

SOUTH PLAINFIELD, N.J., Sept. 21 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced a grant award of approximately $1.6 million from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OPD) to support an ongoing Phase 3 study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF).  The goal of the FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO)

"We are pleased to receive this grant from the FDA to support our ongoing development of ataluren for the treatment of nonsense mutation cystic fibrosis," stated Stuart W. Peltz, Ph.D., President and Chief Executive Officer of PTC Therapeutics.  "In addition to recognizing the potential of ataluren, this grant reflects PTC's long-standing commitment to developing new treatments for patients with rare genetic disorders that severely impact survival and quality of life."

The Phase 3 trial will enroll approximately 200 patients at research centers in North America, Europe and Israel.  The primary goal of the study is to evaluate whether ataluren can improve lung function as measured by forced expiratory volume (FEV1).  Other outcome measures will evaluate whether ataluren can decrease lung infections, reduce the frequency of cough and improve patient-reported quality of life.  Patients are randomized to receive either ataluren (40 mg/kg) or placebo daily for 48 weeks.  Study candidates include patients who are at least six years of age and have CF due to a nonsense mutation.

Patients with CF lack adequate levels of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a chloride channel necessary for norm
'/>"/>

SOURCE PTC Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... , July 11, 2014 , ... part) in, into or from any jurisdiction where to do ... such jurisdiction.  Shire plc ("Shire" or the "Company") ... article this afternoon.  Shire confirms it has held a meeting ... made by Shire without the prior agreement or approval of ...
(Date:7/11/2014)... 2014 Research and Markets  has announced ... - Global Industry Analysis, Size, Share, Growth, Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection ... DNA or RNA) into cells. This technology helps the ... and protein metabolism by affecting the nuclear genes. The ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... labeling and mass spectrometry-based techniques, Mark Chance, PhD, director ... Center for Proteomics and Bioinformatics and professor of physiology ... Center for Proteomics and Bioinformatics; and a research team ... were able to take a high resolution picture of ...
... , , ... Ormsby reports: , , , ... that the Company has engaged the services of Robert B. Nealon, Esq. as ... in Nealon & Associates, P.C., a Washington, D.C. based law and government relations ...
... association studies have uncovered a number of DNA variants ... risk variants lie outside of genes, posing a challenge ... In a report published online today in ... a functional DNA element associated with prostate cancer, lending ...
Cached Biology Technology:Case Western Reserve University-led team takes high resolution photo of a K+ channel 2Case Western Reserve University-led team takes high resolution photo of a K+ channel 3IGEN Networks engages new Director and Chairman of the Board 2IGEN Networks engages new Director and Chairman of the Board 3Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 2Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 3
(Date:7/11/2014)... A new report from the Wildlife Conservation Society ... only help economically valuable species such as lobster, ... also help re-colonize nearby reef areas. , The ... a systematic review of research literature from no-take ... by Dr. Craig Dahlgren, a recognized expert in ...
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... were many fires burning in eastern New South Wales, ... 11. , At 03:35 UTC on July 11 (12:35 ... Aqua passed over eastern New South Wales (NSW), the ... visible image of the region and spotted smoke (light ... MODIS,s thermal bands, are outlined in red. , The ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... for the popular television show "Are You Smarter than a 5th ... The conventional wisdom: rods and cones. The human retina contains ... movement, and about 7 million cones, which in addition detect color. ... not exist. But that might not be true, according to ...
... of all acute leukemias represents a small population of ... standard treatments available today. Though current chemotherapy can produce ... of experiencing a recurrence and dying from the disease. ... rare form of leukemia called acute promyelocytic leukemia (APL), ...
... ANN ARBOR, Mich.---In cells, as in cities, disposing ... is an essential service. In both city and cell, ... New research by University of Michigan cell ... how the cell,s garbage dump and recycling center, the ...
Cached Biology News:Blind mice can 'see' thanks to special retinal cells 2Grant to fund research into eradicating the leukemia stem cell 2Opening the gate to the cell's recycling center 2
... membrane and filter paper sandwiches are composed ... two sheets of thick filter paper that ... filter paper sandwich. These 7 x 8.5 ... immunoblotting fit Ready Gel-sized gels and are ...
... inhibits protein synthesis. Acts by inhibiting ... Reported to induce apoptosis in a ... cells, Jurkat cells, ventricular myocytes, and ... and immediate early gene induction. Selective ...
... The RC DC protein assay kit I provides ... concentration in the presence of reducing agents and ... colorimetric assay. The kit includes reagents and standards ... reagent I, 250 ml RC reagent II, 250 ...
Recommended for use as a cell culture substratum at 0.1-0.2 mg/cm 2 or 5-10 μl/cm 2 . Optimal concentration depends on cell type as well as the application or research objectives. Type B...
Biology Products: